PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD 1,405.00
+80.00 (6.04%)
Sep 8, 2026, 1:30 PM CST
PharmaEssentia Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 549,122 | 173,829 | 204,725 | 114,578 | 143,840 | 78,065 | |
Market Cap Growth | 223.08% | -15.09% | 78.68% | -20.34% | 84.26% | 215.94% |
Enterprise Value | 525,673 | 153,140 | 184,915 | 94,836 | 140,322 | 77,603 |
Last Close Price | 1325.00 | 423.29 | 498.03 | 280.19 | 386.28 | 234.31 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 71.63 | 34.45 | 69.04 | - | - | - |
Forward PE | 42.60 | 25.16 | 41.36 | 31.89 | 69.03 | - |
PS Ratio | 26.46 | 11.12 | 21.03 | 22.44 | 49.91 | 118.91 |
PB Ratio | 14.92 | 5.44 | 7.45 | 4.78 | 11.85 | 18.37 |
P/TBV Ratio | 15.47 | 5.48 | 7.53 | 4.84 | 12.08 | 19.50 |
P/FCF Ratio | 92.56 | 51.64 | 123.13 | - | - | - |
P/OCF Ratio | 66.36 | 32.94 | 81.09 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 25.33 | 9.80 | 19.00 | 18.58 | 48.69 | 118.21 |
EV/EBITDA Ratio | 62.90 | 30.26 | 100.14 | - | - | - |
EV/EBIT Ratio | 66.05 | 31.07 | 106.51 | - | - | - |
EV/FCF Ratio | 88.60 | 45.49 | 111.21 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.04 | 0.05 | 0.13 | 0.13 |
Debt / EBITDA Ratio | 0.12 | 0.16 | 0.47 | - | - | - |
Debt / FCF Ratio | 0.17 | 0.25 | 0.58 | - | - | - |
Net Debt / Equity Ratio | -0.64 | -0.68 | -0.73 | -0.77 | -0.72 | -0.69 |
Net Debt / EBITDA Ratio | -2.88 | -4.32 | -10.88 | 10.12 | 4.57 | 1.08 |
Net Debt / FCF Ratio | -3.95 | -6.49 | -12.08 | 9.25 | 4.81 | 1.15 |
Asset Turnover | 0.54 | 0.46 | 0.33 | 0.24 | 0.27 | 0.11 |
Inventory Turnover | 1.52 | 1.29 | 0.86 | 0.48 | 0.83 | 0.60 |
Quick Ratio | 4.76 | 5.84 | 9.34 | 9.86 | 4.37 | 2.80 |
Current Ratio | 5.28 | 6.21 | 9.94 | 10.64 | 5.24 | 3.49 |
Return on Equity (ROE) | 23.34% | 16.97% | 11.54% | -3.46% | -16.77% | -68.81% |
Return on Assets (ROA) | 12.95% | 9.00% | 3.72% | -5.61% | -11.77% | -30.08% |
Return on Invested Capital (ROIC) | 55.13% | 56.26% | 26.72% | -43.05% | -85.59% | -210.08% |
Return on Capital Employed (ROCE) | 21.10% | 15.10% | 6.10% | -7.60% | -15.90% | -59.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.39% | 2.90% | 1.45% | -0.54% | -0.96% | -3.60% |
FCF Yield | 1.08% | 1.94% | 0.81% | -1.74% | -1.26% | -3.24% |
Dividend Yield | 0.10% | 0.32% | 0.18% | - | - | - |
Payout Ratio | 4.80% | 7.26% | - | - | - | - |
Buyback Yield / Dilution | -0.22% | -0.13% | -3.58% | -13.47% | -9.24% | -7.39% |
Total Shareholder Return | -0.12% | 0.19% | -3.40% | -13.47% | -9.24% | -7.39% |